Synthetic Biology Startups
33 companies tagged Synthetic Biology, with their investors and founders.
Cisterna Biologics develops yeast-engineered mRNA manufacturing technology that can be selectively purified to drive protein expression in human cells. The company targets cost-effective, scalable, and non-immunogenic mRNA production for therapeutic applications.
1 investor
Epinoma develops EpiAmp, a methyl-preserving amplification technology to analyze epigenetic changes and methylation patterns for applications in disease detection, drug development, and patient stratification. The company serves research institutions, pharmaceutical companies, and clinical diagnostic organizations in the biotech and healthcare sectors.
1 investor
Tissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.
1 investor
Molagri develops biopesticides that target harmful insects through specific molecular mechanisms while protecting beneficial insects and the environment, and incorporates resistance modeling to maintain product efficacy over time.
1 investor
Ohmic Biosciences develops engineered proteins and synthetic biology solutions to address diseases in crops. The company creates durable treatments applicable across different agricultural products.
1 investor
Pando develops enzyme design and optimization using machine learning to accelerate the design-build-test-learn cycle for biotechnology applications.
1 investor
SynsoryBio develops protein-based drugs that detect their location in the body and activate only at diseased tissue, with applications across cancer and autoimmune conditions.
1 investor
TareBio operates a platform for developing personalized and population-level vaccines against cancer and infectious diseases by analyzing immune cells already responding to a disease and reverse-engineering the antigens that activate them. The company works in the biotechnology and vaccine development space.
1 investor
Twenty Two develops AI-powered biosecurity infrastructure for screening and monitoring biological threats across the emerging bioeconomy. The platform provides automated customer screening, functional sequence prediction, and model safeguards to help organizations comply with dual-use research regulations.
1 investor